Unibest 优贝德
← Back to patent-cliff list

阿利沙坦酯

Tier C — Watch / trade

Allisartan Isoproxil

上海艾力斯医药科技股份有限公司
Originator
2013
First approval
-
Expiry (public)
No sales data
Peak sales
化学药
Type

Targets:AT1

Brand:信立坦

Indications (approved):高血压

Regional status

US
-
EU
-
China
批准上市
2013-10-24
Japan
-

Synthetic routes & intermediates3 routes

Originator routes × 1Optimised (non-patent) × 2Process routes × 0

Routes are ordered originator first, then optimised / process (non-patent) routes; each lists steps, overall yield and the intermediate table (code / CAS / name) — ready for supplier sourcing and RFQ. Rendered by this site from structured data; no third-party route graphics used.

OriginatorRoute 1Steps 4 · Total yield 0.436 g
Synthetic routes & intermediates Route 1
CodeCAS No.Intermediate
ALIS-003947331-10-4((isopropoxycarbonyl)oxy)methyl 2-butyl-4-chloro-1-((2'-(1-trityl-1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-1H-imidazole-5-carboxylate
ALIS-00435180-01-92-butyl-4-chloro-1-((2'-(1-trityl-1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-1H-imidazole-5-carbaldehyde
ALIS-005947331-22-8((isopropoxycarbonyl)oxy)methyl 2-butyl-4-chloro-1-((2'-(1-trityl-1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-1H-imidazole-5-carboxylate
ALIS-001124750-99-81-((2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-2-butyl-4-chloro-1H-imidazole-5-carboxylic acid
ALIS-002124750-92-12-butyl-4-chloro-1-((2'-(1-trityl-1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-1H-imidazole-5-carboxylic acid
OptimisedRoute 2Steps 5 · Total yield 780.9 g
Synthetic routes & intermediates Route 2
CodeCAS No.Intermediate
ALIS-001124750-99-81-((2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-2-butyl-4-chloro-1H-imidazole-5-carboxylic acid
ALIS-003947331-10-4((isopropoxycarbonyl)oxy)methyl 2-butyl-4-chloro-1-((2'-(1-trityl-1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-1H-imidazole-5-carboxylate
ALIS-00435180-01-92-butyl-4-chloro-1-((2'-(1-trityl-1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-1H-imidazole-5-carbaldehyde
ALIS-005947331-22-8((isopropoxycarbonyl)oxy)methyl 2-butyl-4-chloro-1-((2'-(1-trityl-1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-1H-imidazole-5-carboxylate
ALIS-006124751-00-4(2-butyl-4-chloro-1-((2'-(1-trityl-1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-1H-imidazol-5-yl)methanol
ALIS-007120568-18-52-butyl-5-chloro-3-[[4-[2-(1-trityltetrazol-5-yl)phenyl]phenyl]methyl]imidazole-4-carbaldehyde
OptimisedRoute 3Steps 4 · Total yield 1.78 g
Synthetic routes & intermediates Route 3
CodeCAS No.Intermediate
ALIS-00435180-01-92-butyl-4-chloro-1-((2'-(1-trityl-1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-1H-imidazole-5-carbaldehyde
ALIS-008114772-54-24'-(bromomethyl)-[1,1'-biphenyl]-2-carbonitrile
ALIS-00983857-96-92-butyl-4-chloro-1H-imidazole-5-carbaldehyde
ALIS-010124750-67-04'-((2-butyl-4-chloro-5-formyl-1H-imidazol-1-yl)methyl)-[1,1'-biphenyl]-2-carbonitrile
ALIS-011-2-butyl-4-chloro-1-((2'-cyano-[1,1'-biphenyl]-4-yl)methyl)-1H-imidazole-5-carboxylic acid
ALIS-012-((isopropoxycarbonyl)oxy)methyl 2-butyl-4-chloro-1-((2'-cyano-[1,1'-biphenyl]-4-yl)methyl)-1H-imidazole-5-carboxylate

Frequently asked questions

What are the approved indications of Allisartan Isoproxil?

Approved indications include: 高血压.

When does the Allisartan Isoproxil patent expire?

No public expiry year is available for Allisartan Isoproxil yet; this page updates once verified.

How many synthesis routes are recorded for Allisartan Isoproxil?

3 synthesis routes are recorded; the shortest is 4 steps with 0.436 g total yield. Intermediates in each route carry codes and CAS numbers.

Where can I buy Allisartan Isoproxil intermediates?

All intermediates in Allisartan Isoproxil routes have CAS profiles — you can submit an RFQ per CAS and it enters the Unibest matching pool.

How do I get a quote for Allisartan Isoproxil intermediates?

Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.

Source: cross-verified data (structured fields only) · 2026-09-24